AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) recommended for use within NHS Wales

By David Rowlands, Oct 27 2017 12:38PM

AbbVie, a global research and development based biopharmaceutical company, today announced that its pan-genotypic hepatitis C regimen, Maviret®, has been recommended for use within NHS Wales, following an assessment by the All Wales Medicines Strategy Group (AWMSG). Maviret® is recommended for use for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Chronic hepatitis C is a silent, progressive disease that can lead to liver damage, scarring of the liver (cirrhosis), liver cancer and death . It is estimated that in Wales 12,000 people are living with chronic hepatitis C .

“New treatments, such as Maviret®, offer patients with all the major genotypes of hepatitis C a chance of clearing the virus with as little as 8 weeks of treatment. This is good news for patients who now have a number of treatment choices that can benefit their quality of life and health. Treatment is cost effective and can also make a positive impact on overall public health as the pool of disease is reduced through treatment. It will also help Wales achieve targets in relation to the World Health Organization’s (WHO) elimination agenda,” said Dr Brendan Healy, Consultant in Infectious Diseases & Microbiology, University Hospital of Wales.

Charles Gore, Chief Executive of The Hepatitis C Trust comments, “This is good news for Wales but we now need to see England and Scotland following Wales’s lead quickly if we are to achieve the WHO goal of eliminating hepatitis C as a public health threat by 2030.”

Read more


Hot Topics                                

biosure tht-myhiv-skyscraper tile DR_Logo